Evidence map›Paper›PMID 37111319›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Fabrication of Nanoformulation Containing Carvedilol and Silk Protein Sericin against Doxorubicin Induced Cardiac Damage in Rats.

Mohammad Shariq, Tarique Mahmood, Poonam Kushwaha, Saba Parveen, Arshiya Shamim, Farogh Ahsan, Tanveer A Wani, Seema Zargar, Rufaida Wasim, Muhammad Wahajuddin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Mohammad ShariqDepartment of Pharmacy, Integral University, Lucknow 226026, Uttar Pradesh, India.
Tarique MahmoodDepartment of Pharmacy, Integral University, Lucknow 226026, Uttar Pradesh, India.
Poonam KushwahaDepartment of Pharmacy, Integral University, Lucknow 226026, Uttar Pradesh, India.
Saba ParveenDepartment of Pharmacy, Integral University, Lucknow 226026, Uttar Pradesh, India.
Arshiya ShamimDepartment of Pharmacy, Integral University, Lucknow 226026, Uttar Pradesh, India.
Farogh AhsanDepartment of Pharmacy, Integral University, Lucknow 226026, Uttar Pradesh, India.
Tanveer A WaniDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.ORCID 0000-0001-5623-2685
Seema ZargarDepartment of Biochemistry, College of Science, King Saud University, P.O. Box 2452, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-5622-0841
Rufaida WasimDepartment of Pharmacy, Integral University, Lucknow 226026, Uttar Pradesh, India.
Muhammad WahajuddinInstitute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of Bradford, Bradford BD7 IDP, UK.ORCID 0000-0003-3362-7558
Integral University · INKing Saud University · SAUniversity of Bradford · GB

Funding

Researchers Supporting Program (2021), King Saud University, Riyadh, Saudi Arabia RSP2023R357
6 · The paper itself

Abstract

Nanotechnology has emerged as an inspiring tool for the effective delivery of drugs to help treat Coronary heart disease (CHD) which represents the most prevalent reason for mortality and morbidity globally. The current study focuses on the assessment of the cardioprotective prospective ofanovel combination nanoformulation of sericin and carvedilol. Sericin is a silk protein obtained from

Indexed as

cardioprotectivecarvediloldoxorubicinsericin

Identifiers

PMID37111319
PMCPMC10143780
OpenAlexW4363677914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.